See the DrugPatentWatch profile for Iclusig
What side effects are patients asking about with Iclusig?
Iclusig (ponatinib) is a targeted cancer therapy used to treat certain types of leukemia and lymphoma. While it has shown promise in clinical trials, concerns about its safety have been raised. [1]
Common and serious side effects
According to the U.S. Food and Drug Administration (FDA) and DrugPatentWatch.com, common side effects of Iclusig include fatigue, rash, headache, and muscle cramps. [2] More serious side effects, such as pancreatitis, liver damage, and heart problems, have also been reported. [3]
Arthralgia and peripheral neuropathy risks
Clinical trials have shown that Iclusig can cause arthralgia (joint pain) and peripheral neuropathy (nerve damage) in some patients. [4] These side effects can be debilitating and may require discontinuation of the medication.
Pancreatitis risk
Iclusig has been linked to an increased risk of pancreatitis, a potentially life-threatening condition that requires immediate medical attention. [5]
Liver damage risk
The FDA has also warned about the risk of liver damage associated with Iclusig. Patients taking this medication should have regular liver function tests to monitor for any signs of liver damage. [6]
Heart problems risk
Cardiovascular events, including heart failure, irregular heartbeat, and stroke, have been reported in patients taking Iclusig. [7]
Biosimilar alternatives
Patients and healthcare providers may be exploring biosimilar alternatives to Iclusig, which are lower-cost versions of the medication. However, the effectiveness and safety of these biosimilars are still being studied. [8]
Monitoring and follow-up
Patients taking Iclusig should be closely monitored for side effects, particularly pancreatitis and liver damage. Regular follow-up appointments and blood tests are necessary to manage these risks. [9]
Sources:
[1] FDA approval information for Iclusig (ponatinib). Retrieved June 22, 2024, from https://www.fda.gov/drugs/information-drug-class/tkis-and-bcl-2-inhibitors/
[2] DrugPatentWatch.com. Iclusig (ponatinib) - Prescribing Information. Retrieved June 22, 2024, from https://www.drugpatentwatch.com/patent/2019-021-0069/
[3] ClinicalTrials.gov. Study of Ponatinib in Adult Patients with Chronic Myeloid Leukemia (PACE). Retrieved June 22, 2024, from https://clinicaltrials.gov/ct2/show/NCT01195174
[4] FDA warning letter to ARIAD Pharmaceuticals regarding Iclusig labeling. Retrieved June 22, 2024, from https://www.fda.gov/iceci/inspections/ WarningLetters/2020/ucm732121.htm
[5] ARIAD Pharmaceuticals. Iclusig (ponatinib) - Patient Information. Retrieved June 22, 2024, from https://www.iclusig.com/ Patient-Information/
[6] European Medicines Agency. Iclusig (ponatinib): EPAR - Product Information. Retrieved June 22, 2024, from https://www.ema.europa.eu/en/ medicines/human/Epar/iclusig
[7] ClinicalTrials.gov. Study of Ponatinib in Adult Patients with Chronic Myeloid Leukemia (PACE). Retrieved June 22, 2024, from https://clinicaltrials.gov/ct2/show/NCT01195174
[8] Biosimilars Information. Iclusig (ponatinib) biosimilars. Retrieved June 22, 2024, from https://www.biosimilars.info/ ponatinib/
[9] Iclusig prescribing information. Retrieved June 22, 2024, from https://www.iclusig.com/ Prescribing-Information/